



Dishman Carbogen Amcis Ltd
Dishman Corporate House
Iscon-Bopal Road, Ambli,
Ahmedabad - 380058
Gujarat, India
CIN: L74900GJ2007PLC051338

+91 27 1742 0102
dishman@dishmangroup.com
www.imdcal.com



3rd February, 2025

To, Department of Corporate Services BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. Ref.: Scrip Code No. : 540701 (Equity) : 974556 and 975834 (Debt)	To, The Manager, Listing Department, National Stock Exchange of India Ltd. “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref. : (i) Symbol – DCAL (ii) Series – EQ
--	--

SUB: PRESS RELEASE – MR. STEPHAN FRITSCHI APPOINTED AS NEW CHIEF EXECUTIVE OFFICER (CEO) OF CARBOGEN AMCIS ENTITIES, COMPANY’S WHOLLY OWNED SUBSIDIARIES DUE TO DEPARTURE OF MR. PASCAL VILLEMAGNE, W.E.F. 1ST APRIL, 2025

REF.: DISCLOSURE PURSUANT TO REGULATIONS 30 AND 51 OF SEBI (LODR) REGULATIONS, 2015

Dear Sir,

With reference to the captioned subject, we would like to inform you that Mr. Pascal Villemagne, CEO of CARBOGEN AMCIS entities has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career. He will remain in his role until March 31, 2025.

Further, the company is pleased to announce that Mr. Stephan Fritschi, currently serving as Chief Alliance Officer and deputy CEO, will assume the role of CEO, effective as of April 1, 2025. Mr. Stephan Fritschi has been with the Company for more than 25 years now and is perfectly placed to take the team forward to an exciting future. In this regard, please find enclosed herewith Press Release.

Kindly take this on your record.

Thanking you.

Yours faithfully,

For, Dishman Carbogen Amcis Limited

Shrima Dave
Company Secretary

Encl.: As Above

PRESS RELEASE

The Company announces that its subsidiaries, CARBOGEN AMCIS entities (CARBOGEN AMCIS) Announces Leadership Transition

Ahmedabad, India (February 3, 2025) — Switzerland-based CARBOGEN AMCIS, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, has announced the departure of its current CEO, Pascal Villemagne as of March 31, 2025 and the appointment of his replacement, Stephan Fritschi.

After thirteen years with CARBOGEN AMCIS, the last three thereof as Chief Executive Officer (CEO), Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career. He will remain in his role until March 31, 2025, and facilitate the handover to the new CEO.

“We thank Pascal for his dedication and leadership during a transformational period for CARBOGEN AMCIS,” said Arpit Vyas, Global Managing Director. “Pascal has been instrumental in the turnaround of CARBOGEN AMCIS. During his tenure, Pascal successfully implemented structural changes in the company organization and supported our digital transformation. He paved the way for a bright future for our company, securing CARBOGEN AMCIS’ position as a world leader in the pharmaceutical industry.”

The company is pleased to announce that Stephan Fritschi, currently serving as Chief Alliance Officer and deputy CEO, will assume the role of CEO, effective as of April 1, 2025. “With more than 25 years at CARBOGEN AMCIS, a perfect knowledge of the company and extensive experience in the pharmaceutical market, Stephan Fritschi brings a deep understanding of the company’s operations, values, and strategic direction, he assures continuity in growing the business” stated Christian Eich, Chairman of CARBOGEN AMCIS.

“It has been a privilege to lead CARBOGEN AMCIS. I am incredibly proud of what we have accomplished together, not only during my three years as CEO, but also over the past thirteen years within the company. I have full confidence in Stephan’s ability to steer the company toward even greater success. We will be working together over the coming weeks to ensure a smooth transition.” Said Pascal Villemagne.

“I am honored to take on this role and lead CARBOGEN AMCIS into the future. I look forward to collaborating with the team to continue the progress we have made and to build on the foundations laid by my predecessor, ensuring we continue to deliver value to our customers, employees, and stakeholders.” Commented Stephan Fritschi

The Board of Directors of CARBOGEN AMCIS expressed its gratitude to Pascal Villemagne for his outstanding contributions and commitment to the company, as well as its confidence in Stephan Fritschi to lead CARBOGEN AMCIS into its next phase of growth.

CARBOGEN AMCIS (www.carbogen-amcis.com) is a leading service provider offering a portfolio of drug development and commercialization services to the pharmaceutical and biopharmaceutical industries across all stages of clinical development and product life cycle. Our integrated services and innovative chemistry solutions support timely and safe drug development, allowing customers to better optimize available resources. CARBOGEN AMCIS is a wholly owned subsidiary of Dishman Carbogen Amcis Limited, Ahmedabad, India.

Dishman Carbogen Amcis Limited (www.imdcal.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Carbogen Amcis group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe, China and in India.